L-Dopa is an amino acid and a hormone that is made naturally by a number of plants and animals. In humans, it is created via biosynthesis from the amino acid L-Tyrosine. It is a precursor to several important and powerful neurotransmitters which include Dopamine, Norepinephrine (Noradrenaline) and Epinephrine (Adrenaline). These are collectively known as catecholamines and they play a role in the stimulation and arousal systems in your brain. In its pure form, L-Dopa is considered to be a psychoactive chemical, and can also be used for the treatment of Parkinson’s Disease and a number of other conditions related to lowered levels of the above neurotransmitters (especially Dopamine). As a nootropic, L-Dopa is used to combat depression and anxiety while enhancing mood and improving the ability to concentrate and focus. L-Dopa is sold under the names Levodopa, Sinemet, Madopar, Stalevo, and Prolopa as well as from the herbal extract Mucuna Pruriens. Levodopa is the most effective medicine for relieving symptoms of Parkinson’s disease. It helps reduce tremor, stiffness, and slowness and helps improve muscle control, balance, and walking. It does not affect freezing, dementia, or problems with involuntary (autonomic) functions, such as constipation, urinary problems, impotence, or pain.
Levodopa does not slow the disease process, but it improves muscle movement and delays severe disability. The use of levodopa allows people with Parkinson’s disease to stay independent and able to function for longer periods of time. But the majority of people taking levodopa develop complications caused by long-term levodopa therapy within 5 to 10 years. Movement problems (motor fluctuations) are the most common and troublesome complication.
Parkinson’s disease drug delays onset of age-related macular degeneration
L-DOPA, a routine drug taken by patients suffering from Parkinson’s disease, has been found to delay the onset of age-related macular degeneration (AMD). The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Denver, Colo……..stay tuned for more information following the presentation of the findings.